Lilly(Eli) & Company
NYSE: LLY
$786.29
-$3.03 (-0.4%)
Real Time Data Delayed 15 Min.
LLY Articles
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Published:
Last Updated:
Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include BBVA, Bed Bath & Beyond, Dropbox, Eli Lilly, Netflix, Procter & Gamble, Splunk and Starbucks.
Published:
Last Updated:
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Published:
Last Updated:
Eli Lilly reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
Published:
Last Updated:
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Apple, BHP Billiton, CBS, Eli Lilly, GE, Halliburton, IBM, Schlumberger and Verizon.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Amazon.com, Boeing, Chesapeake Energy, Eli Lilly, Gilead Sciences, Micron Thecnology, NVIDIA, Procter & Gamble...
Published:
Last Updated:
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated: